Anacor Pharma (ANAC) Tops Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Anacor Pharmaceuticals Reports First Quarter 2015 Financial Results
May 6, 2015 4:01 PM EDTPALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced its financial results for the quarter ended March 31, 2015.
We continue to work with our partner Sandoz to optimize the commercial opportunity for KERYDIN® and believe, based on the continued growth in prescriptions, that we are making good progress, said Paul L. Berns, Chairman and Chief Executive Officer of Anacor. In addition, we recently completed enrollment in both of our pivotal Phase 3 studies of AN2728 in patients with mild-to-moderate atopic dermatitis and continue to expect to announce top-line data in the third... More
